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  26 
ABSTRACT 27 
Anti-apoptotic Bcl-2 protein is emerging as an efficient inhibitor of IP3R function, 28 
contributing to its oncogenic properties. Yet, the underlying molecular mechanisms remain 29 
not fully understood. Using mutation or pharmacological inhibition to antagonize Bcl-2’s 30 
hydrophobic cleft, we excluded this functional domain as responsible for Bcl-2-mediated 31 
IP3Rs inhibition. In contrast, the deletion of the C-terminus, containing the trans-membrane 32 
domain, which is only present in Bcl-2α, but not in Bcl-2β, led to impaired inhibition of IP3R-33 
mediated Ca2+ release and staurosporine-induced apoptosis. Strikingly, the trans-membrane 34 
domain was sufficient for IP3R binding and inhibition. We therefore propose a novel model, 35 
in which the Bcl-2’s C-terminus serves as a functional anchor, which beyond mere ER-36 
membrane targeting, underlies efficient IP3R inhibition by (i) positioning the BH4 domain in 37 
the close proximity of its binding site on IP3R, thus facilitating their interaction; (ii) inhibiting 38 
IP3R-channel openings through a direct interaction with the C-terminal region of the channel 39 
downstream of the channel-pore. Finally, since the hydrophobic cleft of Bcl-2 was not 40 
involved in IP3R suppression, our findings indicate that ABT-199 does not interfere with IP3R 41 
regulation by Bcl-2 and its mechanism of action as a cell-death therapeutic in cancer cells 42 
likely does not involve Ca2+ signaling. 43 
  44 
INTRODUCTION 45 
A hallmark of cancer cells is their ability to prolong cell survival by avoiding apoptosis. The 46 
family of B-cell lymphoma-2 (Bcl-2) proteins is a critical regulator of this process [1-5]. It 47 
consists of anti-apoptotic members, including Bcl-2 [6] and Bcl-Xl [7] and pro-apoptotic 48 
members like Bax [8]. All the members of the family share at least one of the four conserved 49 
α-helical motifs, known as Bcl-2 homology (BH1-4) domains [1, 9]. Many of these proteins 50 
exist in more than one isoforms [7, 10-13] and Bcl-2 is not an exception. Two isoforms of 51 
Bcl-2, resulting from alternative splicing, were described: Bcl-2α and Bcl-2β [14]. Most of 52 
the work until now has been done with Bcl-2α, which is the long isoform and which in 53 
addition to the four BH domains contains a C-terminal extension with a putative trans-54 
membrane domain (TMD) (Fig. 1A). In contrast, Bcl-2β has a much shorter C-terminus and 55 
lacks a TMD [14, 15]. While Bcl-2β is mostly detected in cytosolic fractions, the TMD and a 56 
short preceding sequence target Bcl-2α to a variety of intracellular membranes including 57 
mitochondrial, endoplasmic reticulum (ER) and nuclear membranes [16-18]. Bcl-2α is the 58 
more abundant isoform in both healthy and cancer cells and it remains dominant in cancer 59 
cells up-regulating Bcl-2 protein [14, 19]. In virtually all studies published to this date, Bcl-2 60 
refers to Bcl-2α. The anti-apoptotic function of Bcl-2 oncogene was first characterized at the 61 
level of the mitochondria, particularly at the outer mitochondrial membrane where it inhibits 62 
Bax/Bak–mediated apoptosis. The mechanism involves a BH3-dependent interaction, where 63 
the hydrophobic cleft of Bcl-2 formed by the BH3-BH1-BH2 domains sequesters the BH3 64 
domain of the pro-apoptotic members. This prevents Bax/Bak activation and oligomerization 65 
and inhibits the consequent mitochondrial permeabilization and cell death [2, 3, 20, 21].  66 
Ca2+ signaling is another important modulator in cell-fate decisions, which can serve as a 67 
survivor factor promoting cell proliferation, but also as a cell-death inducer [22-25]. Bcl-2 68 
was shown to execute its pro-survival function not only via direct inhibition of pro-apoptotic 69 
proteins but also via suppression of pro-apoptotic Ca2+ signals. This occurs by direct 70 
interaction with inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs) [26-29], the main 71 
intracellular Ca2+ release channels, located at the ER [30-34]. IP3R inhibition by Bcl-2 72 
appears to be an important mechanism that contributes to the oncogenic properties of Bcl-2. 73 
Many cancer cells, including leukemia, lymphoma and lung cancer cells, are addicted to 74 
IP3R/Bcl-2-complex formation for their survival, since tools that disrupt this complex trigger 75 
cell death [35-37]. Over the last years, important insights in the regulation of IP3Rs by Bcl-2 76 
(i.e. Bcl-2α) at the molecular level have been obtained. The suppression of IP3R-mediated 77 
Ca2+ release by Bcl-2 was attributed to the interaction of the BH4 domain of Bcl-2 with a 20 78 
amino acid region (a.a. 1389-1408) located in the central modulatory domain, more 79 
particularly in the domain 3 (Dom 3) (a.a. 923-1581) of IP3R [38, 39]. Previous studies, which 80 
exploited synthetic peptides covering the BH4 domain of Bcl-2 (BH4-Bcl-2), revealed that 81 
this domain is necessary and sufficient to bind to IP3R and to suppress its activity [26, 27, 39, 82 
40]. Nevertheless, the relatively low affinity of inhibition by the BH4 domain (measured in 83 
vitro IC50=30µM) [27, 39] cannot explain the potent inhibitory effect of Bcl-2 full-length 84 
protein in physiological conditions. This Achilles’ heel of the model suggests that additional 85 
domains in Bcl-2 could be responsible for an efficient in cellulo inhibition of IP3R. 86 
Interestingly, the C-terminal domain, containing the last 6th TMD of the IP3R (C-term Dom, 87 
a.a. 2512-2749), which is in close proximity of the channel pore is also targeted by Bcl-2 [41, 88 
42], but the mechanism and significance of this interaction are not completely solved. The 89 
same C-term Dom of IP3R also appeared to be responsible for interaction with other members 90 
of the family: Bcl-Xl and Mcl-1 [41]. 91 
Here, we aimed to identify the molecular determinants in Bcl-2α responsible for its interaction 92 
with the C-term Dom of IP3R and to assess their functional impact on Bcl-2α-mediated 93 
inhibition of the channel. We especially focused on two important functional domains in Bcl-94 
2α, i.e. the hydrophobic cleft, involved in BH3-dependent interactions and the C-terminal 95 
region, containing the TMD, involved in hydrophobic interactions within the membrane 96 
environment (Fig. 1A). Using genetic and pharmacological approaches, we could however 97 
exclude the hydrophobic cleft as a major player in the formation of the Bcl-2α/IP3R complex. 98 
In contrast, we found that Bcl-2α binding to the C-term Dom of IP3R1 depends on the 99 
presence of the C-terminus of Bcl-2α. This region of Bcl-2α is required for efficient inhibition 100 
of IP3Rs in a cellular context and for inhibition of staurosporine (STS) – induced apoptosis. 101 
Furthermore, we demonstrated a direct interaction between a peptide corresponding to the 102 
TMD of Bcl-2α (TMD-Bcl-2) and the purified C-terminal fragment of IP3R1. The TMD-Bcl-103 
2 was able to suppress IP3-induced Ca2+ release (IICR) when applied at high concentrations. 104 
These results suggest that the C-terminal region, and particularly the TMD, of Bcl-2α not only 105 
serves as an anchor for tethering Bcl-2α in the membranes, but is also an important functional 106 
regulator of IP3R activity. Since the TMD is only present in Bcl-2α, but not in Bcl-2β, this 107 
study is the first one hinting towards important functional difference between the two 108 
isoforms with respect to Ca2+-signaling regulation. 109 
  110 
RESULTS  111 
Despite the presence of BH3-domain features in the IP3R sequence, the hydrophobic 112 
cleft of Bcl-2α is dispensable for interaction with the receptor. We performed a sequence 113 
alignment of the BH3 domains of different Bcl-2 proteins with the fragment of the central 114 
modulatory domain of IP3R1 (Dom 3), shown in previous studies to bind Bcl-2 [27, 38, 42]. 115 
This analysis revealed the presence of BH3 motif (a.a. 1332-1342) upstream of the previously 116 
described region in Dom 3 of IP3R targeted by the BH4 domain of Bcl-2 (a.a. 1389-1408) 117 
(Fig. 1A) [43]. Fig. 1B depicts the presence of the conserved LxxxGD/E motif [44] in the 118 
Dom 3 of IP3R and the α-helical secondary structure of this motif as predicted by I-TASSER 119 
web server. To determine whether a BH3-dependent mechanism plays a direct role in the 120 
interaction between Bcl-2α and IP3R we used two different approaches to antagonize the 121 
hydrophobic cleft of Bcl-2α, genetic manipulation and pharmacological inhibition. The 122 
genetic approach is based on mutations in the BH1 domain (replacement of G145R146 by AA 123 
yielding Bcl-2GR/AA) (Fig. 1A), which lead to disruption of the binding between Bcl-2α and 124 
Bax [45-47]. The second approach is based on the use of pharmacological inhibitors like the 125 
BH3-mimetic compounds [48, 49], designed to occupy the hydrophobic cleft, thereby 126 
disrupting interactions between BH3 domain-containing proteins and anti-apoptotic Bcl-2 127 
proteins [48, 49]. Here, we applied ABT-199, a selective Bcl-2 inhibitor which does not target 128 
Bcl-Xl [50]. 129 
First, we validated that both, the GR/AA mutation or the incubation with ABT-199 (3 µM), 130 
prevent Bcl-2α binding to Bax in co-immunoprecipitation experiments. The concentration of 131 
ABT-199 that we used in the experiments is well above the documented subnanomolar 132 
affinity of this compound for Bcl-2 (Ki < 0.01 nM) [50], thus maximizing the potential effect 133 
of ABT-199 on Bcl-2/IP3R interaction. 3xFLAG-tagged proteins (3xFLAG-Bcl-2wt in 134 
presence and absence of ABT-199 or 3xFLAG-Bcl-2GR/AA) were overexpressed in COS-1 135 
cells and immunoprecipitated from the cell lysates using anti-FLAG-loaded agarose beads. 136 
Immunoblots were stained for FLAG and Bax (Fig. 2A). 137 
Next we performed two different sets of GST pull-down experiments, using the two purified 138 
IP3R domains targeted by Bcl-2, GST-Dom 3 (a.a. 923-1581) and GST-C-term Dom (a.a. 139 
2512-2749). To compare the binding properties of the wild-type Bcl-2 protein versus the 140 
mutant for these IP3R fragments we overexpressed 3xFLAG-Bcl-2wt or 3xFLAG-Bcl-2GR/AA 141 
in COS-1 cells. The binding of 3xFLAG-Bcl-2wt to GST-Dom 3 was used as reference and all 142 
binding values were normalized to this control. Our results show that 3xFLAG-Bcl-2GR/AA 143 
remained fully capable of binding to both GST-Dom 3 and GST-C-term Dom to a similar 144 
extent as 3xFLAG-Bcl-2wt (Fig. 2B).  145 
As a second approach, we examined the interaction between Bcl-2wt and the two GST-fused 146 
domains of IP3R in presence or absence of the BH3-mimetic compound ABT-199 (3 µM). 147 
Incubation with ABT-199 did not significantly affect the binding of 3xFLAG-Bcl-2wt to the 148 
GST-Dom 3, nor to the GST-C-term Dom (Fig. 2C).   149 
Taken together these results suggest that the hydrophobic cleft of Bcl-2 is dispensable for its 150 
interaction with IP3R. 151 
The hydrophobic cleft of Bcl-2α does not contribute to the inhibitory effect on IP3Rs. 152 
Bcl-2 overexpression results in dampened IP3R-mediated Ca2+ release in intact cells [27, 29, 153 
39, 51], but whether this effect is mediated through the hydrophobic cleft of Bcl-2 is not 154 
known. To address this question, we monitored the change in cytosolic Ca2+ levels in 155 
response to an IP3R agonist, ATP, using the ratiometric fluorescent Ca2+ dye Fura-2-AM. 156 
Similarly to the GST-pull down experiments, we used the mutation (Bcl-2GR/AA) or ABT-199 157 
to antagonize the hydrophobic cleft of Bcl-2α. Intact COS-1 cells overexpressing 1) 3xFLAG-158 
empty vector, 3xFLAG-Bcl-2wt or 3xFLAG-Bcl-2GR/AA and 2) 3xFLAG-empty vector or 159 
3xFLAG-Bcl-2wt in presence or absence of ABT-199 (3 µM), and co-transfected with 160 
mCherry plasmid were exposed to ATP (0.5 µM). The proper expression of the 3xFLAG-161 
proteins in the COS-1 cells was assessed via Western blotting using anti-FLAG antibody (Fig. 162 
S1A and B). Importantly, the expression levels of 3xFLAG-Bcl-2wt and 3xFLAG-Bcl-2GR/AA 163 
proteins were similar, although 3xFLAG-Bcl-2GR/AA tended to be expressed at slightly higher 164 
levels. In addition, only cells with similar intensity of mCherry, thus similar levels of 165 
3xFLAG-proteins were subjected to measurement. To chelate the free extracellular Ca2+, the 166 
experiments were performed in the presence of BAPTA (3 mM), an extracellular Ca2+ buffer, 167 
ensuring that the ATP-induced [Ca2+] rise is only due to Ca2+ release from intracellular stores. 168 
The ER Ca2+-store content was also assessed by applying thapsigargin (Tg, 1 µM), an 169 
irreversible SERCA inhibitor, in the presence of BAPTA (Fig. S1A and Fig. S1B). 170 
Consistent with our previous studies, overexpression of 3xFLAG-Bcl-2wt inhibited ATP-171 
induced Ca2+ release without affecting the ER Ca2+-stores content [27]. In line with our GST-172 
pull down experiments, neither the overexpression of 3xFLAG-Bcl-2GR/AA (Fig. 3A-C) nor 173 
the presence of ABT-199 (Fig. 4A-D) prevented this effect. The quantitative analysis 174 
indicated that 3xFLAG-Bcl-2wt, 3xFLAG-Bcl-2GR/AA (Fig. 3D) and 3xFLAG-Bcl-2wt in 175 
presence of ABT-199 (Fig. 4E) were equally potent in inhibiting IP3R-mediated Ca2+ release. 176 
Finally, to underpin that IP3R inhibition by Bcl-2α is not affected by ABT-199, we performed 177 
direct IP3R single-channel measurements by using patch-clamp recordings on giant 178 
unilamellar vesicles (GUVs) prepared from the ER membrane fractions of native WEHI7.2 179 
cells, which do not express any of the Bcl-2 isoforms (WEHI7.2 control) or Bcl-2α-180 
overexpressing WEHI7.2 cells (WEHI7.2 Bcl-2). Fig. 4F, G presents a comparison of the 181 
measured IP3R-mediated channel current after application of IP3 (5 μM) and Ca2+ (1 μM). The 182 
results demonstrate a significant inhibition of IP3R activity in the presence of Bcl-2α, 183 
measured as the open probability (NPo). The NPo value of 0.89 ± 0.07 for the WEHI7.2-184 
control cells decreased to 0.26 ± 0.09 for WEHI7.2 Bcl-2 cells. Application of ABT-199 (1 185 
μM) could not alleviate the inhibitory effect of Bcl-2α on IP3R single-channel opening (NPo 186 
0.08 ± 0.05). 187 
Collectively, these functional experiments based on independent approaches exclude a major 188 
contribution of the hydrophobic cleft of Bcl-2α for inhibiting IP3R-mediated Ca2+ flux. 189 
The C-terminal region of Bcl-2α is critical for its interaction with the C-term Dom, but 190 
not with the Dom 3 of IP3R1. After demonstrating that the hydrophobic cleft of Bcl-2α is not 191 
involved in the binding to and inhibition of IP3R, we investigated whether the C-terminal 192 
region containing the TMD of Bcl-2 could serve as an IP3R-interaction domain. We studied 193 
the binding of 3xFLAG-Bcl-2 lacking its C-terminal region (3xFLAG-Bcl-2ΔC) to purified 194 
GST-Dom 3 and GST-C-term Dom using GST-pull-down assays. In these experiments, 195 
consistent with our previous results, 3xFLAG-Bcl-2wt bound with equal efficiency both IP3R 196 
GST-domains [42]. In line with previous data, showing that the BH4 domain of Bcl-2 is 197 
sufficient to bind to the Dom 3 [27, 39], 3xFLAG-Bcl-2ΔC remained capable to bind to this 198 
domain. Yet, the interaction with GST-C-term Dom was severely impaired (Fig. 5A, B). 199 
These results suggest that while the C-terminal region of Bcl-2α is not crucial for interaction 200 
with the Dom 3, it is essential for binding to the C-term Dom of IP3R. 201 
3xFLAG-Bcl-2wt, 3xFLAG-Bcl-2GR/AA and 3xFLAG-Bcl-2ΔC bind to the full-size IP3R. 202 
3xFLAG-Bcl-2 mutants seem to have differential binding properties for the different IP3R 203 
domains. However, the performed FLAG-co-immunoprecipitation experiments with lysates 204 
from COS-1 cells overexpressing 3xFLAG-empty vector, 3xFLAG-Bcl-2wt, 3xFLAG-Bcl-205 
2GR/AA or 3xFLAG-Bcl-2ΔC revealed that we observed that the wild type and both mutated 206 
proteins are able to interact with the endogenous IP3R1 (Fig. S2). These data are consistent 207 
with previous studies showing that the BH4 domain of Bcl-2 is the major determinant for 208 
binding to IP3Rs [27].  209 
We also compared the binding properties of 3xFLAG-Bcl-2wt, 3xFLAG-Bcl-2GR/AA and 210 
3xFLAG-Bcl-2ΔC for endogenous pro-apoptotic Bax. As expected, 3xFLAG-Bcl-2GR/AA failed 211 
to interact with Bax. The truncated Bcl-2 displayed equal efficiency for binding Bax as the 212 
wild type Bcl-2, confirming that the hydrophobic cleft is the major binding determinant in 213 
Bcl-2 interactions with pro-apoptotic proteins (Fig. S2).  214 
The TMD of Bcl-2α directly interacts with the C-term Dom of IP3R1. As a next step we 215 
performed pull-down experiments using neutravidin-coated beads that captured the 216 
biotinylated peptides corresponding either to the TMD of Bcl-2 (biotin-TMD-Bcl-2) or to a 217 
control version in which several hydrophobic residues were substituted by charged amino 218 
acids (biotin-TMD-Bcl-2-CTR) in the presence of either purified parental GST or purified 219 
GST-C-term Dom of IP3R1. After incubation and washing steps, the resulting pull-down 220 
samples were analysed via immunoblotting using anti-GST antibody (Fig. 5C). This analysis 221 
revealed a direct interaction between the GST-C-term Dom of IP3R1 and biotin-TMD-Bcl-2.  222 
The lack of the C-terminus leads to loss of Bcl-2α ability to suppress IP3R-mediated Ca2+ 223 
release. Next, we studied the role of the C-terminus in Bcl-2α’s inhibitory function on IP3R-224 
mediated Ca2+ signaling. Similar experiments were performed as described in Figure 4, 225 
comparing the effect of 3xFLAG-Bcl-2wt versus 3xFLAG-Bcl-2ΔC overexpression on ATP-226 
induced IP3R-mediated Ca2+ release. In contrast to 3xFLAG-Bcl-2wt, which reduced the 227 
amount of Ca2+ release in response to ATP (0.5 µM), 3xFLAG-Bcl-2ΔC was not able to 228 
suppress IP3R-mediated Ca2+ release (Fig. 6). The 3xFLAG-proteins displayed similar 229 
expression levels (Fig. S1C), indicating that the failure of 3xFLAG-Bcl-2ΔC to inhibit IP3Rs is 230 
not due to a lower expression level compared to the 3xFLAG-Bcl-2wt protein. The ER Ca2+ 231 
store content was not changed in either of the conditions pointing that the difference in ATP-232 
induced Ca2+ rise is not due to a decreased ER Ca2+-store content (Fig. S1C).  233 
The TMD of Bcl-2α suppresses IICR in permeabilized cells and in single-channel 234 
recordings. We demonstrated that the TMD of Bcl-2α directly binds to the C-term Dom of 235 
IP3R and that Bcl-2ΔC does not inhibit IP3R-mediated Ca2+ release. Next, we assessed whether 236 
the TMD of Bcl-2α by itself could affect the Ca2+-flux properties of the IP3R. Therefore, we 237 
performed unidirectional 45Ca2+ flux assays in saponin-permeabilized mouse embryonic 238 
fibroblasts (MEFs), in which non-mitochondrial Ca2+ stores were loaded with 45Ca2+. After 239 
loading, the unidirectional Ca2+ flux was measured in the presence of EGTA (1 mM) and in 240 
presence of Tg (4 µM). We quantified 45Ca2+ release triggered by IP3 (3 µM) in presence or 241 
absence of different concentrations of the synthetic peptides corresponding to the TMD of 242 
Bcl-2 or its mutated version. Peptides were applied 2 min before till 2 min after IP3 243 
application. All conditions were matched to the vehicle control (DMSO). Data are plotted as 244 
the fractional loss (%/2 min) over time. These experiments indicated that high concentrations 245 
of TMD-Bcl-2 (30 µM and higher), but not of TMD-Bcl-2-CTR, suppress IICR without 246 
affecting ER Ca2+ level (Fig. 7A, B). To further underpin these observations, IP3R1 single-247 
channel recordings were performed using the nuclear-membrane patch-clamp technique on 248 
isolated nuclei obtained of triple-IP3R-knockout DT40 cells ectopically expressing IP3R1 249 
[52]. This approach allows a direct measurement of the activity of the IP3R1 channel. IP3R1 250 
single-channel activity was recorded in response to submaximal concentrations of IP3 (1 µM) 251 
in the presence of ATP (5 mM) and Ca2+ (200 nM). Fig. 7C shows different representative 252 
traces of IP3R1 single-channel openings at a pipette holding potential of -100 mV in control 253 
conditions or in the presence of TMD-Bcl-2 or TMD-Bcl-2-CTR peptides, both at 60 µM 254 
final concentrations. TMD-Bcl-2 decreased the Po of the IP3R1 channel from about 0.25 in the 255 
control conditions to about 0.15, whereas the TMD-Bcl-2-CTR peptide did not have any 256 
significant impact. 257 
Bcl-2α requires its TMD to suppress STS-induced apoptosis. Finally, we studied the 258 
potency of overexpressed 3xFLAG-Bcl-2wt, 3xFLAG-Bcl-2GR/AA and 3xFLAG-Bcl-2ΔC to 259 
protect against STS, an apoptotic trigger that acts in part through Ca2+ signalling [53]. As a 260 
marker of apoptosis, we monitored the cleavage of poly-(ADP-ribose)-polymerase 1 261 
(PARP1), which is a downstream target of activated Caspase-3. Compared to the control cells 262 
(transfected with an empty vector), the overexpression of 3xFLAG-Bcl-2wt significantly 263 
reduced the levels of cleaved PARP1 upon STS treatment (1 µM, 6h). 3xFLAG-Bcl-2GR/AA 264 
failed to prevent PARP1 cleavage, in line with its failure to bind Bax (Fig. S2). Despite the 265 
fact that 3xFLAG-Bcl-2ΔC was equally efficient as the 3xFLAG-Bcl-2wt to bind endogenous 266 
Bax (Fig. S2), it was much less efficient in preventing STS-induced apoptosis in COS-1 cells 267 
(Fig. 8).  268 
  269 
DISCUSSION 270 
Here, we demonstrate that the efficient in cellulo suppression of IP3R activity by Bcl-2α 271 
protein requires the C-terminal region, containing the TMD, but not the hydrophobic cleft of 272 
Bcl-2α. Consistent with this finding, Bcl-2α lacking the TMD is less effective to protect cells 273 
against Ca2+-dependent pro-apoptotic stimuli like staurosporine. Since the TMD is present 274 
only in Bcl-2α, but not in Bcl-2β, our study is the first one that indicates a possible difference 275 
between the functional effects of the Bcl-2 isoforms on IP3R activity (Fig. 9) and thus on 276 
Ca2+-dependent apoptosis. Furthermore, our data indicate that BH3-mimetic compounds like 277 
ABT-199, which selectively antagonize Bcl-2, do not interfere with the functional regulation 278 
of IP3Rs by Bcl-2.  279 
Using genetic and pharmacological approaches, we firmly ruled out a major role for the 280 
hydrophobic cleft of Bcl-2 in inhibiting IP3R function, despite the presence of previously 281 
suggested [54] or identified throughout this study putative BH3 motifs within the IP3R 282 
sequence (Fig. 1B). This is in striking contrast to the regulation of IP3Rs by Bcl-Xl, very 283 
recently described to occur via a BH3-dependent mechanism, involving an interaction 284 
between the hydrophobic cleft of Bcl-Xl and 2 BH3 motifs in the C-term Dom of IP3R [54, 285 
55]. Disruption of these interactions resulted in diminished cell viability. The authors 286 
speculated that similar BH3-dependent interactions might underlie the Bcl-2/IP3R complex 287 
[55]. Therefore, our work suggests that despite the similarities in their structure and function 288 
as inhibitors of the canonical Bax/Bak-dependent apoptosis, Bcl-2 and Bcl-Xl target and 289 
regulate IP3Rs by different mechanisms. The data reported here might concede another 290 
striking difference in addition to the documented selective function of Bcl-2 versus Bcl-Xl in 291 
regulating IP3Rs at the level of their BH4 domains [27]. Of note, selective BH3-mimetic 292 
molecules that could occupy the hydrophobic cleft of Bcl-2, but not that of Bcl-Xl, have been 293 
developed, indicating important differences in the molecular determinants contributing to the 294 
hydrophobic cleft of Bcl-2 and Bcl-Xl [50]. Hence, the BH3 motifs present in the IP3R might 295 
be suited for binding the hydrophobic cleft of Bcl-Xl, but not the one of Bcl-2. In addition, the 296 
hydrophobic cleft of Bcl-2 was recently excluded as a major contributor in the inhibition of 297 
another family of intracellular Ca2+-release channels, namely ryanodine receptors (RyRs) 298 
[45].  299 
Previously we reported that the absence of the 6th TMD of IP3R results in impaired Bcl-2 300 
binding to the C-terminus of the channel [42]. Here, we demonstrate that the TMD of Bcl-2α 301 
is also required for this interaction, which likely occurs within the ER membrane. We propose 302 
that the TMD of Bcl-2α provides a concentration effect of Bcl-2 and its BH4 domain. This 303 
indicates that the membrane-dependent interaction between Bcl-2α and IP3R is critical for 304 
effective in cellulo inhibition of IP3R-mediated Ca2+ signaling and subsequent protection 305 
against Ca2+-dependent apoptosis. Our results also hint towards an unappreciated function of 306 
the TMD of Bcl-2α beyond its anchoring role for protein insertion into the membranes. 307 
Indeed, the TMD by itself is sufficient to inhibit IP3Rs as shown in unidirectional 45Ca2+ 308 
fluxes and single IP3R-channel recordings, correlating with previous findings that TMDs of 309 
other Bcl-2 family members play an important role in the protein functioning [56, 57]. 310 
However, it should be noted that even 60 µM TMD-Bcl-2 only partially inhibited IP3R-311 
mediated Ca2+ release in permeabilized cells, indicating that also other Bcl-2 domains, 312 
particularly the BH4 domain, are required for efficient IP3R inhibition by Bcl-2α. Of note, the 313 
binding of Bcl-2α lacking its C-terminal region to the purified Dom 3 or to the full-length 314 
IP3Rs was not significantly disturbed, supporting the idea that the BH4 domain of Bcl-2 is 315 
sufficient for binding to the Dom 3 of IP3R and that this binding indeed occurs with relatively 316 
high affinity as documented via previous surface plasmon resonance analysis. We propose a 317 
model according to which the efficient IP3R inhibition relies on a complex multi-domain 318 
binding between Bcl-2α and IP3R, involving interactions between the BH4 domain of the 319 
former and the Dom 3 of the channel, and between the C-terminal regions of both proteins. 320 
We propose that the C-terminus of Bcl-2α (Fig. 9C), but not the one of the Bcl-2β (Fig. 9B), 321 
mediates the inhibitory effect of the BH4 domain by increasing its local concentration in the 322 
proximity of the Dom 3 of IP3R. In addition, the dual targeting of IP3Rs by Bcl-2α via its C-323 
terminus and its BH4 domain might affect the conformational flexibility of the IP3R, by 324 
locking it in a rigid conformation and limiting the opening of the Ca2+-channel pore in 325 
response to IP3 (Fig. 9). A particularly challenging aspect of our model is that, based on the 326 
most recent cryo-electron microscopy high-resolution structure of the IP3R1 [58], the 6th 327 
TMD of the IP3R may not be readily available for interaction with other proteins. Yet, the 328 
published structure is in the absence of IP3 and thus likely represents the closed state. Hence, 329 
changes in the IP3R structure might arise in different IP3/Ca2+ conditions impacting the 330 
accessibility of the 6th TMD of the IP3R to proteins like Bcl-2. Vice versa, it is also possible 331 
that the structure of IP3Rs loaded with Bcl-2 is different from the structure of IP3Rs in the 332 
absence of Bcl-2, thereby impacting the structural environment of the 6th TMD of IP3R. 333 
Finally, we also would like to note that the molecular foundation for this model is mainly 334 
based on binding studies, using IP3R1-expression constructs and the electrophysiological 335 
analysis of IP3R1 channels. However, some of the cell models used for the functional analysis 336 
mainly express IP3R3 and IP3R1 isoforms [59]. As such, we anticipate that the important role 337 
of Bcl-2’s TMD for efficient IP3R inhibition is not limited to IP3R1 channels, but further 338 
detailed molecular and functional work would be needed to firmly proof this. Of note, the 339 
BH4-domain-binding site present in IP3R1 is completely conserved in IP3R2 and IP3R3 [60], 340 
consistent with Bcl-2’s ability to bind to the central domain of all three IP3R isoforms [27]. 341 
The importance of the multi-domain interaction between IP3Rs and Bcl-2 is underpinned by 342 
the fact that peptides antagonizing Bcl-2 at its BH4 domain (like Bcl-2/IP3 Receptor 343 
Disrupter-2; BIRD-2) are able to trigger pro-apoptotic Ca2+ signaling in a variety of cancer-344 
cell models, including lymphoma, leukemia and lung cancer cells [35, 37, 61]. Thus, 345 
development of inhibitors targeting Bcl-2’s TMD and interfering with the IP3R/Bcl-2 complex 346 
at the level of the TMD/C-term Dom interaction might further potentiate BH4-domain-347 
antagonizing tools by helping to destabilize the Bcl-2/IP3R complex. Yet, given the 348 
hydrophobic nature of TMD/C-term Dom interactions, such small molecule developments 349 
may prove to be very challenging.  350 
We conclude that efficient IP3R regulation by Bcl-2α requires the TMD, a unique feature that 351 
discriminates Bcl-2α from Bcl-2β. Bcl-2α, via its TMD, likely “concentrates” its BH4 domain 352 
in the proximity of the central, modulatory domain of the IP3R, thereby facilitating its ability 353 
to efficiently suppress IP3R-mediated Ca2+ signaling and subsequent apoptosis. 354 
  355 
MATERIALS AND METHODS 356 
Peptides 357 
The following peptides, obtained from Life Tein (Hillsborough, NJ, USA) with purity ≥ 85% 358 
were used: the peptide corresponding to the TMD of Bcl-2, Bcl-2-TMD: 359 
KTLLSLALVGACITLGAYLGHK (also used with biotin tag); the control peptide containing 360 
several mutations of hydrophobic residues, Bcl-2-TMD-CTR: 361 
KTRRSLADRGACRTRGAYDGHK (also used with biotin tag) and the peptide used to 362 
compete with the 3xFLAG tag, Anti-DYKDDDDK-tag peptide: 363 
MDYKDHDGDYKDHDIDYKDDDDK. 364 
Antibodies 365 
The following antibodies were used: mouse monoclonal HRP-conjugated anti-FLAG M2 366 
(1:1000; Sigma-Aldrich, Munich, Germany); mouse anti-FLAG M2 antibody (1:1000, Sigma-367 
Aldrich); mouse monoclonal HRP-conjugated anti-Bcl-2 (1:1000, Santa Cruz Biotechnology, 368 
Santa Cruz, CA, USA), mouse anti-GST (1:5000; Cell Signaling Technology, Danvers, 369 
Massachusetts, USA); mouse monoclonal anti- βActin (1:20 000, Sigma-Aldrich); rabbit anti-370 
BAX (1:1000; Santa Cruz), rabbit anti-IP3R1 (1:1000; Rbt03 [62]); rabbit polyclonal anti-371 
PARP-1 (1:1000, Alexis-Enzo Life Sciences, Farmingdale, NY, USA) as primary antibodies 372 
and secondary mouse and rabbit anti-IgG HRP conjugated antibodies (1:2500, Cell Signaling 373 
Technology). 374 
Plasmids, constructs and protein purification 375 
pCMV24-3xFLAG-Myc constructs for expression of 3xFLAG–Bcl-2 and 3xFLAG-Bcl-376 
2GR/AA were obtained as previously described [45]. The 3xFLAG-Bcl-2ΔC mutant, in which a 377 
stop codon was introduced at amino acid W214, was developed via PCR site-directed 378 
mutagenesis utilizing the following primers: Forward: 5' 379 
GTTTGATTTCTCCTGACTGTCTCTGAAGACTC 3' and Reverse: 5' 380 
GAGTCTTCAGAGACAGTCAGGAGAAATCAAAC 3'. 381 
BL21(DE3) Escherichia coli cells were transformed with pGEX-6p2 constructs containing 382 
cDNAs of parental GST, GST-Dom 3 of IP3R1 (a.a. 923-1581) or GST-C-term Dom of IP3R1 383 
(a.a. 2512–2749), which were obtained as previously described [42]. The expressed parental 384 
GST or GST-fusion proteins were purified as previously described [42] and dialysed against 385 
standard phosphate-buffered saline (PBS) without Ca2+ and Mg2+ (Invitrogen, Merelbeke, 386 
Belgium) using Slide-A-Lyzer cassettes with a cut-off of 10 kDa (Thermo Fisher Scientific, 387 
Pittsburg, PA, USA). The concentration of the purified and dialysed proteins was determined 388 
using the Bradford assay (Sigma–Aldrich). Purity and quality were assessed after SDS–PAGE 389 
via total protein staining using the GelCode Blue Stain Reagent (Thermo Scientific, Rockford, 390 
IL, USA). 391 
Cell culture and transfections 392 
All media and supplements used in this paper were purchased from Life Technologies (Ghent, 393 
Belgium) unless stated otherwise. COS-1 cells were cultured at 37°C, 10% CO2 in Dulbecco's 394 
Modified Eagle's medium (DMEM), containing 10% fetal calf serum (Sigma-Aldrich), 100 395 
IU/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml fungizone and 2 mM glutamax. MEF 396 
cells were cultured at 37°C in a 10% CO2 incubator in DMEM/Ham's F12 medium 397 
supplemented with 10% fetal calf serum, 3.8 mM L-glutamine, 85 IU/ml penicillin and 398 
85 μg/ml streptomycin. 399 
24 hours after seeding COS-1 cells were transiently transfected with empty p3xFLAG-Myc-400 
CMV-24 (3xFLAG-empty) or with the same vector containing either Bcl-2wt or the mutants 401 
Bcl-2GR/AA or Bcl-2ΔC. For co-IP and pull-down experiments JETPrime transfection reagent 402 
(Polyplus Transfections, Illkirch, France) was used according to the manufacturer’s 403 
instructions. For single-cell cytosolic [Ca2+] measurements COS-1 cells were seeded in two-404 
chamber slides. The same construct, in combination with a pcDNA 3.1(-) mCherry encoding 405 
vector at a 3:1 ratio as selection marker, were introduced 24 hours after seeding using X-406 
tremeGene HP DNA (Roche, Basel, Switzerland) as a transfection reagent according to the 407 
manufacturer's instructions. 408 
GST-pull down assays 409 
48 hours after transfection COS-1 cells overexpressing 3xFLAG-Bcl-2wt, 3xFLAG-Bcl-Bcl-410 
2GR/AA or 3xFLAG-Bcl-2ΔC were harvested and lysed in a buffer containing 25 mM Tris-HCl 411 
(pH 7.5), 150 mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 1% Triton X-100 and protease 412 
inhibitor cocktail tablets (Roche). After 30 min of incubation at 4°C the clear lysates were 413 
collected via centrifugation for 2 min at 10 000 rpm at 4°C. Parental GST, GST-Dom 3 or 414 
GST-C-term Dom (0.5 µM) were incubated together with 100 µg lysate in the lysing buffer 415 
(final volume 500 µl) at 4°C. After 1 hour the GST-proteins, used as bait, were immobilized 416 
on glutathione-Sepharose 4B beads (GE Healthcare, Diegem, Belgium) for 1.5 hour at 4°C. In 417 
order to study the effect of the BH3-mimetic compound, 3 µM ABT-199 (Active Biochem, 418 
Germany) or the vehicle control DMSO (Sigma-Aldrich, St Louis, MO) was added during the 419 
last hour of incubation. The beads were washed 5 times with the Triton X-100 buffer. The 420 
GST-complexes were eluted in 40 µl 2×LDS (Life Technologies) supplemented with 1:200 β-421 
mercaptoethanol by boiling for 5 min at 95°C. Samples (10 µl) were analyzed via SDS-PAGE 422 
and the quantification was performed as previously described [63].  423 
Biotin-pull down assays 424 
Equal amounts of the peptides (30 µg), biotin-TMD-Bcl-2 or biotin-TMD-Bcl-2-CTR, 425 
dissolved in 100% DMSO were incubated with 0.35 µM purified GST-C-term Dom of IP3R1 426 
or parental GST (control) in interaction buffer (50 mM Tris-HCl, 200 mM NaCl, 0.1% NP-40, 427 
1% BSA and protease inhibitor cocktail, pH 7.0) in a final volume of 400 µl. The incubation 428 
was performed over night at 4°C in a head-over-head rotator. The biotinylated peptides were 429 
immobilized on neutravidin agarose beads (Thermo Fisher Scientific, Pierce, Erembodegem, 430 
Belgium) and placed in a head-over-head rotator for 2 hours at 4°C. The beads were washed 7 431 
times with the interaction buffer and the peptide-protein complexes were eluted by incubating 432 
the beads with 35 µl LDS supplemented with 1:200 β-mercaptoethanol for 3 min at 95°C. The 433 
eluates were collected after centrifuging at 2000 g for 1 min, using spin columns (Pierce) and 434 
10 µl was analysed on NuPAGE 4–12% Bis/Tris SDS–polyacrylamide gels using MES/SDS-435 
running buffer (Invitrogen). 436 
FLAG-co-immunoprecipitation assay 437 
48 hours after transfection COS-1 cells overexpressing the control vector 3xFLAG-empty, 438 
3xFLAG-Bcl-2wt, 3xFLAG-Bcl-Bcl-2GR/AA or 3xFLAG-Bcl-2ΔC were harvested and lysed in 439 
buffer containing 10 mM Hepes (pH 7.5), 0.25% NP-40, 142  mM KCl, 5 mM MgCl2, 2 mM 440 
EDTA, 2 mM EGTA and protease inhibitor cocktail tablets (Roche) as described for GST-pull 441 
down assay. 100 µg of lysate was mixed with 30 µl anti-DYKDDDDK-tag conjugated resin 442 
(Biolegend, San Diego, CA) in the lysis buffer in total volume of 400 µl. The samples were 443 
incubated for 2.5 hours using a head-over-head rotor at 4°C. The beads were washed 2 times 444 
with washing buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.5% sodium 445 
deoxycholate and 0.1% SDS) via centrifugation for 1 min at 3000g using spin columns. The 446 
FLAG-complexes were eluted by competitive incubation with the Anti-DYKDDDDK-tag 447 
peptide (10 µg, dissolved in 50mM Tris-HCl and 150mM NaCl) for 30 min at 15°C. To the 448 
resulting eluates, collected via centrifugation for 1 min at 500g, 25 µl LDS supplemented with 449 
1:200 β-mercaptoethanol was added. 15 µl of each sample was analysed on NuPAGE 4–12% 450 
Bis/Tris SDS–polyacrylamide gels using MES/SDS-running buffer. 451 
Single-cell cytosolic Ca2+ imaging 452 
Fura-2-AM [Ca2+] measurements in COS-1 cells were performed as previously described 453 
[27]. The effect of ABT-199 was studied by incubating the cells with 3 µM of the compound 454 
or DMSO for 1 hour (during the incubation procedure with Fura-2 AM). BAPTA (3 mM) was 455 
added for 1 minute prior to the stimulation with ATP or Tg to chelate all free extracellular 456 
Ca2+. Cytosolic Ca2+ rises in response to 0.5 μM ATP or 2.5 μM Tg were measured in 457 
mCherry-positive (excitation 546 nm, emission 610 nm) and Fura-2-loaded cells. Intracellular 458 
cytoplasmic Ca2+ concentrations were calculated as previously described [27]. 459 
Unidirectional 45Ca2+-flux assay 460 
The unidirectional 45Ca2+-flux experiments were performed in permeabilized MEFs as 461 
previously described [27]. IICR was triggered during the unidirectional 45Ca2+-efflux phase by 462 
the addition of 3 μM IP3 for 2 min. Peptides were added 2 min before IP3 till 2 min after IP3. 463 
IICR was plotted as fractional loss, representing the amount of Ca2+ leaving the store in a 2-464 
min time period divided by the total store Ca2+ content at that time point as a function of time 465 
[64].  466 
Preparation of GUVs and electrophysiological analysis 467 
Isolation of the ER-containing membrane fractions from control and Bcl-2-expressing 468 
WEHI7.2 cells and preparation of the GUVs were carried out as described previously [65]. 469 
GUVs were prepared from the 1:5 mixtures of the ER-containing fraction with 10:1 470 
diphytanoylphosphatidylcholine/cholesterol lipid combination (5 mM). The Patch-clamp 471 
experiments were carried out using Axopatch 200B amplifier and pClamp 10.0 software 472 
(Molecular Devices, Union City, CA) for data acquisition and analysis. Patch pipettes were 473 
fabricated from borosilicate glass capillaries (World Precision Instr., Inc., Sarasota, FL) on a 474 
horizontal puller (Sutter Instruments Co., Novato, CA) and had a resistance in the range of 7-475 
10 MΩ. Prepared vesicles were immersed in a bath solution containing 150 mM KCl, 10 mM 476 
Hepes, 5 mM glucose, pH 7.2. Patch pipettes were filled with the same solution. 477 
Isolation of nuclei and electrophysiological analysis 478 
Isolated DT40 nuclei were prepared by homogenization as previously described [52]. A 3 μl 479 
aliquot of nuclear suspension was placed in 3 ml of bath solution which contained 140 mM 480 
KCl, 10 mM Hepes, 500 μM BAPTA and 246 nM free Ca2+, pH 7.1. Nuclei were allowed to 481 
adhere to a plastic culture dish for 10 min prior to patching. Single IP3R channel potassium 482 
currents (ik) were measured in the on-nucleus patch clamp configuration using pCLAMP 9 483 
and an Axopatch 200B amplifier (Molecular Devices, Sunnydale, CA, USA) as previously 484 
described [66]. Pipette solution contained 140 mM KCl, 10 mM Hepes, 1 μM IP3, 5 mM 485 
ATP, and 200 nM free Ca2+ as well as 60 μM TMD-Bcl-2 or TMD-Bcl-2-CTR peptides. 486 
Traces were consecutive 3 s sweeps recorded at −100 mV, sampled at 20 kHz and filtered at 5 487 
kHz. A minimum of 15 s of recordings were considered for data analyses. Pipette resistances 488 
were typically 20 MΩ and seal resistances were >5 GΩ. Single channel openings were 489 
detected by half-threshold crossing criteria using the event detection protocol in Clampfit 9. 490 
We assumed that the number of channels in any particular nuclear patch is represented by the 491 
maximum number of discrete stacked events observed during the experiment. Only patches 492 
with one apparent channel were considered for analyses.  493 
Apoptosis induction and analysis 494 
COS-1 cells were transiently transfected with 3xFLAG-vectors and treated with 1 μM STS 495 
(Sigma-Aldrich). After 6h the cells were harvested and lysed in a buffer containing 25 mM 496 
Hepes (pH 7.5), 1% Triton X-100, 10% glycerol, 0.3 M NaCl, 1.5 mM MgCl2, 1 mM DTT, 497 
2 mM EDTA, 2 mM EGTA and protease inhibitor cocktail tablets (Roche). Apoptosis 498 
progression was monitored via Western-blotting analysis of PARP1 cleavage in 10 µg total 499 
lysate.  500 
Sequence alignment and secondary-structure predictions 501 
The amino acid sequences of the BH3 domains of Bcl-2 proteins and the Dom 3 of IP3R were 502 
taken from the National Center for Biotechnological Information’s nonredundant database. 503 
The I-TASSER v 2.1 webserver [67, 68] was used to predict the secondary structure of the 504 
BH3-like motif identified in the Dom 3 of IP3R1. I-TASSER builds protein models using 505 
iterative assembling procedures and multiple threading alignments from template structures 506 
libraries. An estimate of accuracy of the predictions is given by the confidence score. The 507 
most accurate I-TASSER model was downloaded as PDB file and imported in PyMOL, a 508 
molecular graphic software (http://www.pymol.org). 509 
Statistical analysis 510 
Two-tailed unpaired Student's t-tests were performed when two conditions were compared. 511 
When comparing three or more conditions a repeated measure ANOVA with Bonferroni post 512 
test was performed. * indicates significantly different results with p < 0.05. 513 
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FIGURE LEGEND 712 
Fig. 1 The Dom 3 of IP3R1 contains a BH3 motif. A: Linear representation of Bcl-2 and 713 
IP3R1. Bcl-2α is depicted in blue with its BH domains and the trans-membrane domain 714 
(TMD). The two functional domains of interest, the hydrophobic cleft formed by BH3-BH1-715 
BH2 domains and the C-terminus (C), are indicated with black lines. The C-terminal region, 716 
containing the TMD, is present in Bcl-2α but not in Bcl-2β. The G145 and R146 residues 717 
located in the BH1 domain were mutated to yield Bcl-2GR/AA. Bcl-2 was truncated at W214 718 
residue to yield Bcl-2ΔC, which correlates with Bcl-2β. A schematic representation of IP3R1 is 719 
depicted in green. The Bcl-2-binding fragments of IP3R used in this study, the domain 3 (Dom 720 
3) and the C-terminal domain containing the last TMD (C-term Dom), are indicated with 721 
black lines and the six TMDs are shown as black bars. The exact BH4-binding site in the 722 
Dom 3 is represented in light grey (BH4-BS). The BH3-like motif in the Dom 3 is represented 723 
in yellow. B: The Dom 3 of IP3R1 contains a BH3 motif. Left: Sequence alignment 724 
between the BH3 domains of Bcl-2 family members and the Dom 3 of IP3R1 reveals the 725 
presence of the conserved residues (LxxxGD/E, pointed in red), required for a typical BH3 726 
motif (46). Right: A secondary structure prediction of the putative BH3 motif of IP3R1 727 
present in the Dom 3 sequence, predicted by the I-TASSER web server and drawn using 728 
PyMol. The predicted BH3 motif within the Dom 3 is depicted in yellow and the conserved 729 
residues in red. 730 
Fig. 2 Bcl-2GR/AA and Bcl-2wt exposed to ABT-199 fail to bind pro-apoptotic Bax, but 731 
remain capable of binding the Dom 3 and the C-term Dom of IP3R. A: Representative 732 
FLAG-co-immunoprecipitation experiment for detection of the 3xFLAG-Bcl-2/Bax 733 
interaction is shown. Overexpressed 3xFLAG-Bcl-2wt (in absence and presence of 3 µM 734 
ABT-199) or 3xFLAG-Bcl-2GR/AA was immunoprecipitated from COS-1 cell lysates by anti-735 
FLAG-loaded agarose beads. The immunoreactive blots were stained with antibody against 736 
FLAG and Bax. 0.1 µg and 0.5 µg of total COS-1 lysates were used as input for the 3xFLAG-737 
proteins and Bax respectively. The experiments were performed 3 times utilizing each time 738 
independently transfected cells and freshly prepared lysates. B: Representative GST-pull 739 
down experiments with COS-1 cell lysates for comparing the binding of overexpressed 740 
3xFLAG-Bcl-2wt and 3xFLAG-Bcl-2GR/AA or C: The immunoreactive bands from 3 741 
independent experiments, utilizing each time independently transfected cells and freshly 742 
prepared lysates, were quantified and normalized to the binding of 3xFLAG-Bcl-2wt to GST-743 
Dom 3, which was set as 1. The data are plotted as mean ± S.E.M. D: 3xFLAG-Bcl-2wt in 744 
absence and presence of 3 µM ABT-199 to the GST-Dom 3 and GST-C-term Dom are shown. 745 
The samples were analyzed via Western blot and stained with anti-FLAG antibody. The 746 
binding to the GST was used as a negative control. 0.1 µg of total COS-1 lysates was used as 747 
input. E: The immunoreactive bands from 3 independent experiments, utilizing each time 748 
independently transfected cells and freshly prepared lysates, were quantified and normalized 749 
to the binding of 3xFLAG-Bcl-2wt to GST-Dom 3, which was set as 1. The data are plotted as 750 
mean ± S.E.M. 751 
Fig. 3 Bcl-2GR/AA remains capable of inhibiting agonist-induced Ca2+ release. A-C: 752 
Intracellular Ca2+ release in response to 0.5 µM ATP was followed in the mCherry-positive 753 
Fura-2-AM loaded COS-1 cells overexpressing 3xFLAG-empty vector (A), 3xFLAG-Bcl-2wt 754 
(B) or 3xFLAG-Bcl-2GR/AA (C). The free extracellular Ca2+ was buffered by addition of 3 mM 755 
BAPTA. The obtained Fura-2 fluorescence signals (λ380/λ340) were calibrated and 756 
representative traces are plotted as [Ca2+]. D: Quantitative analysis of the amplitude of the 757 
ATP-induced Ca2+ signals from at least 3 independent experiments (n > 80 cells) is plotted as 758 
mean ± S.E.M. 759 
Fig. 4 ABT-199 does not impact Bcl-2’s ability to suppress IP3R activity in single-cell 760 
measurements and in patch-clamp single-channel recordings. A-D: Intracellular Ca2+ 761 
release in response to 0.5 µM ATP was followed in the mCherry-positive Fura-2-AM loaded 762 
COS-1 cells overexpressing 3xFLAG-empty vector (A, C) or 3xFLAG-Bcl-2wt (B, D) in 763 
absence (A, B) or presence of 3 µM ABT-199 (C, D). The free extracellular Ca2+ was 764 
buffered by addition of 3 mM BAPTA. The obtained Fura-2 fluorescence signals (λ380/λ340) 765 
were calibrated and representative traces are plotted as [Ca2+]. E: Quantitative analysis of the 766 
amplitude of ATP-induced Ca2+ signals from at least 3 independent experiments (n > 80 cells) 767 
is plotted as mean ± S.E.M. F: Representative IP3R currents in ER-containing membrane 768 
fractions from control (WEHI7.2 CTR) (top) and Bcl-2-expressing WEHI7.2 cells without 769 
(middle) or with (bottom) application of 1 μM ABT-199. The IP3R activity was triggered by 770 
5 μM IP3 and 1 μM Ca2+ G: The mean levels of IP3R activity (NPo) under these conditions are 771 
summarized and the data are plotted as mean ± S.E.M. The total number of recordings for 772 
each condition is indicated within every bar. H: Western blot analysis of the expression levels 773 
of Bcl-2, IP3R1 and IP3R3 in WEHI7.2 CTR and WEHI7.2 Bcl-2 cells. 5 µg of total lysate 774 
was loaded and the immunoreactive bands were stained against Bcl-2, IP3R1, IP3R3 and actin.  775 
Fig. 5 Bcl-2 requires its TMD for binding to the C-term Dom, but not to the Dom 3 of 776 
IP3R1 A: Representative GST-pull down experiments to compare the binding properties of 777 
3xFLAG-Bcl-2wt versus 3xFLAG-Bcl-2ΔC overexpressed in COS-1 cells for GST-Dom 3 and 778 
GST-C-term Dom are shown. The binding to GST is used as a negative control. 0.1 µg of 779 
total COS-1 lysates was used as input. B: The immunoreactive bands from 4 independent 780 
experiments, utilizing each time independently transfected cells and freshly prepared lysates, 781 
were quantified and normalized to the binding of 3xFLAG-Bcl-2wt to GST-Dom 3, which was 782 
set as 1. The data are plotted as mean ± S.E.M. C: Representative biotin-pull down 783 
experiment to study the binding of biotin-TMD-Bcl-2 or biotin-TMD-Bcl-2-CTR peptide to 784 
the purified GST or GST-C-term Dom is shown. The immunoblots were stained for GST. The 785 
experiment was performed 3 times. 0.2 µg of purified GST and GST-C-term Dom was loaded 786 
as input. The double line indicates that two parts of the same immunoblot and exposure time 787 
were merged together.  788 
Fig. 6 Bcl-2ΔC fails to inhibit IP3R-mediated Ca2+ release. A-C: Intracellular Ca2+ release in 789 
response to 0.5 µM ATP was followed in the mCherry-positive Fura-2-AM loaded COS-1 790 
cells overexpressing 3xFLAG-empty vector (A), 3xFLAG-Bcl-2wt (B) or 3xFLAG-Bcl-2ΔC 791 
(C). The free extracellular Ca2+ was buffered by addition of 3 mM BAPTA. The obtained 792 
Fura-2 signals (λ380/λ340) were calibrated and representative traces are plotted as [Ca2+]. D: 793 
Quantitative analysis of the amplitude of the ATP-induced Ca2+ signals from 5 independent 794 
experiments (n > 110 cells) is plotted as mean ± S.E.M.  795 
Fig. 7 The TMD of Bcl-2 is sufficient to inhibit IP3Rs in permeabilized cell systems and 796 
single-channel recordings. A: Typical experiment of unidirectional 45Ca2+ fluxes in 797 
permeabilized MEFs. Ca2+ release was induced by 3 µM IP3 (grey bar) in control condition or 798 
in presence of 60 µM peptides, TMD-Bcl-2 or TMD-Bcl-2-CTR (black bar). The results are 799 
plotted as fractional loss after 2 min of incubation with IP3 minus the fractional loss before the 800 
addition of IP3 (%/2 min) as a function of time. B: Quantification of the IICR from 5 801 
independent experiments. The values of IICR measured as fractional loss were calculated as 802 
percentage of the IICR in control condition, which was set as 100%. C: Representative IP3R1 803 
single-channel recordings from DT40 cells ectopically expressing IP3R1 evoked by 1 µM IP3 804 
at 200 nM Ca2+ and 5 mM ATP, in control condition or in presence of the TMD-Bcl-2 or 805 
TMD-Bcl-2-CTR peptides. D: Histogram depicting the open probability (Po) ± SD for the 806 
IP3R1 under the previously described conditions. The total number of recordings for each 807 
condition is indicated within every bar. 808 
Fig. 8 The TMD of Bcl-2 is required for STS-induced apoptosis. A: Western-blot analysis 809 
for monitoring PARP1 cleavage upon staurosporine (STS) treatment (1 μM for 6 h) in COS-1 810 
cells overexpressing 3xFLAG-empty, 3xFLAG-Bcl-2wt, 3xFLAG-Bcl-2GR/AA or 3xFLAG-811 
Bcl-2ΔC. 7 µg of total cell lysate were loaded and the immunoblots were stained for PARP1, 812 
FLAG and Actin. B: Quantification of the ratio of the immunoreactive bands of cleaved over 813 
full-length PARP1 from 4 independent experiments, utilizing each time independently 814 
transfected COS-1 cells and freshly prepared lysates. The ratio of cleaved over full-length 815 
PARP1 obtained for control cells was set as 100% and the other ratios were normalized to this 816 
value. The data are plotted as ± S.E.M. 817 
Fig. 9 Model for inhibition of IP3Rs by Bcl-2 proteins. Left side of the picture shows linear 818 
representation of the multi-domain interaction between Bcl-2 proteins and IP3R. On the right 819 
side these interactions are depicted within the ER membrane environment. A) Without IP3 820 
present, IP3R is in closed conformation and no Ca2+ release occurs. B) Upon stimulation, IP3 821 
binds to the N-terminal ligand-binding domain of IP3R and leads to change in the 822 
conformation of the channel from closed to open state. This results in IP3R-mediated Ca2+ 823 
release. Bcl-2β, which similarly to our Bcl-2ΔC, contains the BH4 domain, but lacks the TMD 824 
might result in ineffective binding and regulation of the channel in cellulo. C) Efficient IP3R 825 
inhibition by Bcl-2α in cellulo requires multi-domain interaction between the two proteins, 826 
which involves binding of the BH4 domain of Bcl-2 to the Dom 3 of IP3R and binding 827 
between their C-termini. Here, we hypothesize that due to this multi-domain interaction, the 828 
IP3R is “locked” in a rigid conformation leading to decreased Ca2+ release through the 829 
channel even in presence of IP3. We propose a model, in which the interaction between the 830 
TMD of Bcl-2α and the C-term Dom of IP3R can “concentrate” the BH4 domain in the 831 
proximity of the Dom 3 by serving as an anchoring mechanism (indicated with an anchor). 832 
This “concentration effect” could overcome the inherent low affinity of inhibition by the BH4 833 
domain. In addition to its anchoring role, the TMD of Bcl-2α has an inhibitory effect by itself. 834 









